

Swart, AC, van Rooyen, D, du Toit, T, Heyns, B, Molphy, J, Wilson, M, Leahy, R and Atkin, SL

Circulating adrenal and gonadal steroid hormones heterogeneity in active young males and the contribution of 11-oxy androgens

<https://researchonline.ljmu.ac.uk/id/eprint/24962/>

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Swart, AC, van Rooyen, D, du Toit, T, Heyns, B, Molphy, J ORCID logo
ORCID: <https://orcid.org/0000-0003-0803-2907>, Wilson, M, Leahy, R and Atkin, SL (2024) Circulating adrenal and gonadal steroid hormones heterogeneity in active young males and the contribution of 11-oxy

LJMU has developed **LJMU Research Online** for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk



OPEN

Circulating adrenal and gonadal steroid hormones heterogeneity in active young males and the contribution of 11-oxy androgens

Amanda C. Swart^{1,2,8}✉, Desmaré van Rooyen¹, Therina du Toit¹, Bianca Heyns^{1,2}, John Molphy³, Mathew Wilson⁴, Roisin Leahy⁵ & Stephen L. Atkin^{6,7,8}

The classical androgens, testosterone and dihydrotestosterone, together with dehydroepiandrosterone, the precursor to all androgens, are generally included in diagnostic steroid evaluations of androgen excess and deficiency disorders and monitored in androgen replacement and androgen suppressive therapies. The C11-oxy androgens also contribute to androgen excess disorders and are still often excluded from clinical and research-based steroids analysis. The contribution of the C11-oxy androgens to the androgen pool has not been considered in androgen deficiency. An exploratory investigation into circulating adrenal and gonadal steroid hormones in men was undertaken as neither the classical androgens nor the C11-oxy androgens have been evaluated in the context of concurrent measurement of all adrenal steroid hormones. Serum androgens, mineralocorticoids, glucocorticoids, progestones and androgens were assessed in 70 healthy young men using ultra high performance supercritical fluid chromatography and tandem mass spectrometry. Testosterone, 24.5 nmol/L was the most prominent androgen detected in all participants while dihydrotestosterone, 1.23 nmol/L, was only detected in 25% of the participants. The 11-oxy androgens were present in most of the participants with 11-hydroxyandrostenedione, 3.37 nmol, in 98.5%, 11-ketoandrostenedione 0.764 in 77%, 11-hydroxytestosterone, 0.567 in 96% and 11-ketotestosterone: 0.440 in 63%. A third of the participants with normal testosterone and comparable 11-ketotestosterone, had significantly lower dehydroepiandrosterone ($p < 0.001$). In these males 11-hydroxyandrostenedione ($p < 0.001$), 11-ketoandrostenedione ($p < 0.01$) and 11-hydroxytestosterone ($p < 0.006$) were decreased. Glucocorticoids were also lower: cortisol ($p < 0.001$), corticosterone ($p < 0.001$), cortisone ($p < 0.006$) 11-dehydrocorticosterone ($p < 0.001$) as well as cortisol:cortisone ($p < 0.001$). The presence of dehydroepiandrosterone was associated with 16-hydroxyprogesterone ($p < 0.001$), which was also significantly lower. Adrenal and gonadal steroid analysis showed unexpected steroid heterogeneity in normal young men. Testosterone constitutes 78% of the circulating free androgens with the 11-oxy androgens abundantly present in all participants significantly contributing 22%. In addition, a subset of men were identified with low circulating dehydroepiandrosterone who showed altered adrenal steroids with decreased glucocorticoids and decreased C11-oxy androgens. Analysis of the classical and 11-oxy androgens with the additional measurement of dehydroepiandrosterone and 16-hydroxyprogesterone may allow better diagnostic accuracy in androgen excess or deficiency.

¹Department of Biochemistry, Stellenbosch University, Stellenbosch 7600, South Africa. ²Department of Chemistry and Polymer Science, Stellenbosch University, Stellenbosch 7600, South Africa. ³Research Institute of Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, UK. ⁴Institute of Sport, Exercise and Health, University College London, London WC1E 6BT, UK. ⁵Data Science Centre, School of Population Health, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin 2, Ireland. ⁶Royal College of Surgeons in Ireland, Busaiten, Bahrain. ⁷Weill Cornell Medicine Qatar, Doha, Qatar. ⁸These authors jointly supervised this work: Amanda C. Swart and Stephen L. Atkin. ✉email: acswart@sun.ac.za

Keywords Androgen replacement therapy, Hypogonadism, 11 β -hydroxyandrostenedione (11OHA4 11OHAD11OHAn), 11-ketotestosterone (11KT), Dehydroepiandrosterone (DHEA), Cytochrome P450 11 β hydroxylase (CYP11B1)

Diagnostic quantitative androgen analysis is essential to investigate androgen excess disorders, primary or secondary hypogonadism, and to determine androgen levels in replacement or suppressive therapies in men. Although total testosterone (T) is clinically measured for androgen sufficiency, only the free form of T is bioactive which is estimated indirectly using the free androgen index. However, bioactive androgens are not limited to T alone. Active functional androgens bind and activate the androgen receptor (AR) and regulate androgen-responsive genes which are critical in the development and maintenance of male sexual characteristics. Steroid metabolism is complex, yielding potent functional steroids that are not all measured in clinical practice.

Dehydroepiandrosterone (DHEA) is the precursor to all androgens that can be divided into two classes: the classical androgens and the C11-oxy androgens. The C11-oxy androgens differ from the classical androgens only in that they have either a hydroxy or oxo group at carbon 11 (the latter also generally referred to as a keto group). The classical androgens include androstenedione (A4), T and dihydrotestosterone (DHT) and their inactive metabolites. The C11-oxy androgens include 11-hydroxyandrostenedione (11OHA4), 11-hydroxytestosterone (11OHT), 11-ketoandrostenedione (11KA4), 11-ketotestosterone (11KT), 11-hydroxydihydrotestosterone (11OHDHT), 11-ketodihydrotestosterone (11KDHT) and their inactive metabolites¹. The classical androgens are produced primarily in the gonads and in the adrenal albeit to a lesser degree and with the exception of dihydrotestosterone (DHT) and the respective metabolites as shown in Fig. 1. It was generally accepted for decades, that the only androgens of importance were the classical androgens, T and DHT. In women, it was believed that testosterone produced in the adrenal was the only androgen source. The C11-oxy androgens produced in the adrenal were not considered in the context of normal androgens in either gender. Since the C11-oxy androgens




Figure 1. Steroid biosynthesis in the adrenal, gonads and peripheral tissue. Adrenal production, boxed, black dotted lines and gonadal production, boxed, black solid lines. Reactions are catalysed by CYP17A1, cytochrome P450 17 α -hydroxylase; CYP21A2, cytochrome P450 21-hydroxylase; CYP11B1, cytochrome P450 11 β -hydroxylase; CYP11B2, aldosterone synthase; 3 β HSD2, 3 β -hydroxysteroid dehydrogenase type 2; 11 β HSD, 11 β -hydroxysteroid dehydrogenase; 17 β HSD, 17 β -hydroxysteroid dehydrogenase and SRD5A, steroid 5 α -reductase. Steroids include the androgen precursor: DHEA, dehydroepiandrosterone; (i) classical androgens: A5, androstenediol; A4, androstenedione; DHT, dihydrotestosterone; T, testosterone; AST, androsterone; 3 α Adiol, 5 α -androstane-3 α ,17 β -diol; (ii) C11-oxy androgens: 11OHA4, 11 β -hydroxyandrostenedione; 11KA4, 11 ketoandrostenedione; 11OHT, 11 β -hydroxytestosterone; 11KT, 11-ketotestosterone; 11OHDHT, 11 β -hydroxydihydrotestosterone; 11KDHT, 11-ketodihydrotestosterone; 11OHASt, 11 β -hydroxyandrosterone; 11KASSt, 11-ketoandrosterone; 11OH3 α DIOL, 5 α -androstan-3 α ,11 β ,17 β -triol; 11K3 α DIOL, 5 α -androstan-3 α ,17 β -diol-11-one. (iii) progesterones: P5, pregnenolone; 17OHP5, 17 α -hydroxypregnenolone; P4, progesterone; 17OHP4, 17 α -hydroxyprogesterone; 16OHP4, 16 α -hydroxyprogesterone; (iv) mineralo- and glucocorticoids: DOC, 11-deoxycorticosterone; CORT, corticosterone; 18OHCORT, 18-hydroxycorticosterone; ALDO, aldosterone; 11-DHCORT, 11-dehydrocorticosterone. Blue boxed steroids, glucocorticoids; green boxed steroids, classical androgens; orange boxed steroids, C11-oxy androgens.

include active androgens, 11KT, 11KDHT, and 11OHDHT², these steroids add to the overall androgenicity of the androgen steroid pool in both males and females, supplementing the action of the classical active androgens.

The metabolic pathways originating from DHEA therefore form classical androgens and C11-oxy androgens yielding potent downstream androgens. In these pathways, the classical androgens and the C11-oxy androgens contribute active functional androgens, T, DHT, 11KT, 11OHDHT and 11KDHT to the endogenous androgen pool (Fig. 1). The C11-oxy progesterones which may potentially also form potent downstream androgens, and the C11-oxy androgens are only produced in the adrenal gland by cytochrome P450 11 β -hydroxylase (CYP11B1), an enzyme generally known to catalyse the production of cortisol. We have shown that CYP11B1 as well as aldosterone synthase (CYP11B2) which catalyses the production of aldosterone (ALDO), also catalyses the biosynthesis of 11OHA4, 11OHT, 21-deoxycortisol (21dF) and 11 β -hydroxyprogesterone (11OHP4). These steroids are subsequently metabolised by 11 β -hydroxysteroid dehydrogenase by converting the hydroxyl group at carbon 11 to an oxo (keto) group in the adrenal and peripheral tissue^{3–5}. 11 β HSD2 has long only been associated with the conversion or inactivation of cortisol to cortisone. The conversion of 11OHA4 and 11OHT by 11 β HSD2 yields 11KA4 and 11KT, respectively, with the subsequent production of 11OHDHT from 11OHT and 11KDHT from 11KT, resulting in potent active androgens capable of binding and activating the AR.

Studies using validated methods report circulating 11OHA4 and 11KT are 2- to 3- fold higher in young males (12–18 years) compared to younger boys⁶ and all four circulating C11-oxy androgen concentrations are reported in ages 21 to 95 years. 11KT concentrations were comparable between studies, though 11OHA4, and 11KA4 concentrations varied between twofold and tenfold, respectively^{7,8}; only one study having included 11KDHT and downstream metabolites, 11 β -hydroxyandrosterone (11OHA4) and 11-ketoandrosterone (11KAST)⁷. Another study reported circulating 11OHA4, 11KA4 and 11KT levels in men 19–59 years of age, though 11OHT was undetectable⁹.

Androgen excess conditions show high C11-oxy androgens, such as classic congenital adrenal hyperplasia (CAH); 21-hydroxylase deficiency (21OHD); polycystic ovary syndrome (PCOS); prostate cancer (PCa); benign prostate hyperplasia (BPH) and premature adrenarche; however, due technical measurement difficulties, 11OHA4, 11OHT, 11KA4, 11KT, 11OHP4 and 21dF evaluations are scarce. Their specific and accurate measurement is important as 11KT is the predominant active androgen in castration-resistant prostate cancer (CRPC)¹⁰ with both 11OHA4 and 11KDHT detected in PCa tissue, tissue homogenates, together with 11KA4, 11KT and 11OHT in serum and plasma^{11–13}. Moreover, in BPH patients, 11OHP4, 11-ketoprogesterone (11KP4) and 11-ketodihydroprogesterone (11K-DHP4) are found in the circulation and in prostate tissue¹². These data suggest that the C11-oxy androgens contribute to 11KDHT levels in vivo. In addition, it is possible that T replacement therapy and anti-androgen therapy may affect the regulation of the C11-oxy androgens, potentially modulating AR interactions and downstream consequences.

The technical difficulties measuring the classical and C11-oxy androgens in the context of the adrenal hormone pool have limited their clinical evaluation and assessments; therefore, this study was to undertake a comprehensive, exploratory analysis of all circulating adrenal and gonadal steroids in healthy male subjects, determining the contribution of the C11-oxy androgens to the overall steroid profile using state of the art ultrahigh performance supercritical fluid chromatography and tandem mass spectrometry (UHPSFC-MS/MS).

Results

Demographic characteristics of participants

There were 71 participants with a mean age of 25.1 years. Participants were mainly of Arab (54%) or Black (27%) ethnicity. Descriptive statistics of all participants are presented in Table 1. Participant demographics showed participants did not differ significantly on any demographic characteristics ($p > 0.05$).

UHPSFC-MS/MS analysis of free unconjugated adrenal and gonadal steroid hormones

Circulating mineralocorticoids, glucocorticoids and androgens (Supple. file, Supple. Table 1) and many steroids, being below the lower limit of detection (LOD) (Supple. Table 2) were therefore not detected. The classical androgens that were not detected were 5 α DIONE and 3 α DIOL and the C11-oxy androgens not detected were 11OH-5 α DIONE, 11K-5 α DIONE, 11OHDHT, 11KDHT, 11OHA4, 11KAST and 11OH3 α ADIOL. The C11-oxy progesterones that were not detected included 21dF, 21dE, Pdione, 11 α OHP4, 11 α OH-DHP4, 11 β OHP4, 11KP4, 11 β OH-DHP4, 11KDHP4, 11OHPdiol, alfaxalone, 11OH-Pdione, 11K-Pdione, and 11K-Pdiol. DOC was the only adrenal steroid not detected at all while others were detected but at low frequencies: 11-deoxycortisol (0.37–2.15 nmol/L, 6/70), 18OHCORT (1.64–32.96 nmol/L, 4/70), ALDO (1.0–15.15 nmol/L, 3/70). Two C11-oxy steroids were only detected in three participants, 11K3 α ADIOL (1.28, 2.76 nmol/L, 2/70) and 3,11diOH-DHP4 (3.4 nmol/L, 1/70), and therefore not included in further analysis. Progesterones detected and not included in analysis were DHP4 (6.58 nmol/L, 1/70). Pdiol (7.36 nmol/L, 1/70) and pregnanetriol (22.26 nmol/L, 1/70).

Steroids subsequently included in analyses are listed in Table 2, showing the percentage at which each steroids was detected above lower limit of quantification (LLOQ) enabling accurate quantification and below the LLOQ but above the LOD. Steroids detected below the LOD in more than 75% of participant were not included in analyses.

Adrenal and gonadal steroids present at frequencies higher than 25% were there analysed and included mineralocorticoids, glucocorticoids and androgens. The steroid profile of one participant differed markedly from other profiles in the cohort. All the steroids analysed were below the LOD except for T, possibly indicative of an underlying clinical condition and was subsequently was excluded from analysis.

Overall (N = 71)	
Age	
Mean (SD)	25.1 (4.77)
Median (Q1, Q3)	24.0 (21.0, 28.0)
Ethnicity	
Arab	38 (53.5%)
Black	19 (26.8%)
White	12 (16.9%)
Asian	2 (2.8%)
Exercise	
Mean (SD)	13.4 (5.61)
Median (Q1, Q3)	12.0 (11.3, 14.0)
Height (cm)	
Mean (SD)	181 (11.5)
Median (Q1, Q3)	181 (172, 188)
Body mass (kg)	
Mean (SD)	78.6 (15.2)
Median (Q1, Q3)	76.0 (65.4, 88.8)
BMI	
Mean (SD)	23.8 (2.72)
Median (Q1, Q3)	23.7 (21.7, 25.3)
BMI category	
Underweight/normal	48 (67.6%)
Overweight/obese	21 (29.6%)
BSA	
Mean (SD)	1.99 (0.243)
Median (Q1, Q3)	1.93 (1.79, 2.17)

Table 1. Demographic characteristics all participants (n = 71).

Steroid	Above LLOQ (%)	Below LLOQ (%)	Below LOD (%)
Testosterone (T)	100.00	0.00	0.00
Cortisol	100.00	0.00	0.00
Cortisone	100.00	0.00	0.00
Corticosterone (CORT)	82.86	17.14	0.00
11-Dehydrocorticosterone (11-DHCORT)	78.57	21.43	0.00
16 α hydroxyprogesterone (16OHP4)	77.14	21.43	1.43
11 α -hydroxytestosterone (11OHT)	70.00	25.71	4.29
11 α -hydroxyandrostenedione (11OHA4)	51.43	47.14	1.43
Dihydrotestosterone (DHT)	15.71	11.43	72.86
Progesterone (P4)	12.86	12.86	74.29
Androstenedione (A4)	8.57	74.29	17.14
17 α hydroxyprogesterone (17OHP4)	2.86	40.00	57.14
Dehydroepiandrosterone (DHEA)	1.43	84.29	14.29
11-ketoandrostenedione (11KA4)	0.00	77.14	22.86
Androstenediol (A5)	0.00	71.43	28.57
11-ketotestosterone (11KT)	0.00	62.86	37.14
17 α -hydroxypregnenolone (17OHP5)	0.00	62.86	37.14
Pregnenolone (P5)	0.00	28.57	71.43

Table 2. Representation of steroid detected in 70 healthy young males at frequencies above 25%. Percentage (%) represents the number of participants in which each steroid was detected above the lower limit of detection (LLOQ), below the LLOQ but above the limit of detection (LOD) and undetected below the LOD.

Analysis of steroids present at frequencies higher than 25% in participants

Steroid analysis of the participant group ($n = 70$) showed that while T, 24.5 nmol/L, was detected in all participants falling within the normal range, the hormone spanned a wide range 7.76–47.3 nmol/L. T precursors, A5 and A4, which were detected in 72% and 83% of participants, respectively, showed A4 concentrations 2.7-fold lower than A5. DHT, the potent SRD5A metabolite of T, was detected in far fewer participants, only 27% participants had detectable concentrations. No classical inactive androgens were detected (Fig. 1). Although the classical androgen levels were higher than the C11-oxy androgen levels, the latter were detected in a more participants with 11OHA4, 11OHT, 11KA4 and 11KT detected in 98.6, 95.7, 77 and 63% of the participants, respectively. 11OHA4 was detected at highest concentration followed by 11KA4 with 11OHT and 11KT which were all lower than 1 nmol/L. Taken together the C11-oxy androgens were present at far lower levels than the classical androgens.

Although the C11-oxy androgens were detected, no C11-oxy progesterones were detected. All of the progesterones were present at far lower concentrations than androgens with pregnenolone (P5) and progesterone (P4) detected in ~25% of participants. Of interest was 16 α -hydroxyprogesterone (16OHP4), the product of P4, which was detected in 98.6% of participants, the most abundant progesterone detected.

Also detected in all participants were the glucocorticoids, cortisol and corticosterone (CORT) and their respective inactive forms, cortisone and 11-dehydrocorticosterone (11-DHCORT). Cortisol and cortisone were the most abundant steroids at 338 and 55.8 nmol/L, respectively with means all within the normal range. Deoxycortisol, the precursor steroid of cortisol was detected at very low levels in only 8% of participants. The inactive metabolites of cortisol and CORT, catalysed by 11 β HSD2, cortisone and 11-DHCORT, were detected at lower levels than their active precursors, respectively. In addition, CORT levels as well as cortisol:cortisone were all within normal ranges. The downstream metabolite in the mineralocorticoid pathway, 18-hydroxycorticosterone (18OH-CORT) was detected in only four participants and aldosterone (ALDO) in three participants.

Upon further inspection it was evident that some participants had very low cortisol and cortisone concentrations together with low cortisol:cortisone. Cluster analysis showed that DHEA in these participants were within the lower normal range of circulating DHEA. We therefore analysed adrenal and gonadal steroids dividing the participants into two groups: those in the lower tertile (6.9 nmol/L), comprising 34% of the participants, and those with DHEA concentrations above (66%). Participant demographics of the participants with DHEA below and DHEA above 7 nmol/L showed participants in the two groups did not differ significantly on any demographic characteristics ($p > 0.05$) (Supple. Table 3.)

Comparing participants with low circulating DHEA (DHEA < 7 nmol/L) to those with DHEA > 7 nmol/L (Table 3), showed that although steroid profiles differed considerably, the classical androgen (A5, A4, T, DHT) levels remained comparable between the two groups. In contrast, the C11-oxyandrogens with the exception of 11KT were significantly lower in the group with low DHEA. In addition, together with significantly lower DHEA, the progesterones detected, P5, 17OHP5 and 16OHP4 were also significantly lower. The active glucocorticoids, cortisol and CORT, their inactive forms, cortisone and 11-DHCORT as well as cortisol:cortisone were also significantly lower in the group with low DHEA. Further analysis also showed that the presence of DHEA was significantly associated with 16OHP4 ($p < 0.001$) (Suppl. Table 4). The presence of DHEA was not significantly associated with any other steroid ($p > 0.05$).

Considering the mean steroid values of subjects with a DHEA lower than 7 nmol/L, the data clearly showed that the steroid profiles of these males differed markedly when compared to males with higher DHEA levels. Mean steroid concentrations of all steroids measured in this study were lower in males with DHEA lower than 7 nmol/L (Fig. 2), with data showing overall lower adrenal steroids in designated pathways.

Discussion

This novel study is the first analysis of circulating adrenal and gonadal steroids that included mineralocorticoids, glucocorticoids, progestins and androgens, providing a circulating free-steroid profile in young men. Testosterone was the dominant free circulating classical androgen followed by A4 and DHEA with the levels in accord with the literature with the average mean concentration and range, 1.5–6.0 nmol/L for A4 and 15–40 nmol/L for DHEA between the ages of 18–40 years^{14,15}. Interestingly, DHT was not detected in all participants, and the inactive metabolites of the classical androgens, 3 α Adiol and AST were not present at all. This may be due to 3 α Adiol and AST circulating in their conjugated forms (99% glucuronidated and/or sulphated)¹⁶ which was not measured in our investigation. Identification and quantification of steroids present at low concentrations would be enhanced by measuring both conjugated as well as free, unconjugated steroids, with only the latter measured in our study. Certain steroids that ionise poorly therefore require to be present at higher concentrations for detection and accurate quantification. The chromatographic separation of numerous steroids, whilst also ensuring the elimination of crosstalk or interference between steroids is challenging. Unique molecular masses of ionised steroids were chosen to identify and quantify (qualifiers and quantifiers) steroids thereby allowing the identification and most accurate quantification of all gonadal and adrenal steroids in a single step. Our findings suggest that the measurement of specific steroid combinations, some of which are not currently included or considered in clinical evaluations of conditions or diseases, could improve the accuracy of diagnosing androgen related conditions¹⁷. It may also lead to better treatment regimens for T replacement or suppression therapies^{18,19}. Androgen deficiency resulting from the hypothalamic-pituitary-gonadal axis dysfunction has received far more attention in men than in women with many features common to both genders—bone density reduction, altered mood states, depression and increased anxiety, impaired cognition, hot flushes, sexual symptoms, decreased muscle mass and increased body fat. Androgen deficiency may not be easily recognised in women as many symptoms are characteristic of the menopause. Since T as well as DHEA levels fall with ageing^{15,20,21}, the contribution of the C11-oxy androgens needs to be determined to see if these steroids have an increased androgen contribution in both genders. It is possible that both 11OHA4 and 11OHT produced in the adrenal become a more important

STEROID nmol/L	Overall (n = 70)	DHEA > 7 nmol/L (n = 47)	DHEA < 7 nmol/L (n = 23)	P-value
Dehydroepiandrosterone (DHEA) _u				
Mean (SD)	12.1 (9.07)	16.1 (8.58)	4.04 (1.44)	<0.001
Median (Q1, Q3)	9.64 (5.19, 18.1)	13.5 (9.64, 20.6)	3.45 (3.45, 5.09)	
Min–Max	0.487–52.7	6.93–52.7	0.487–6.64	
Androstenediol (A5)				
Mean (SD)	4.40 (2.44)	4.79 (2.79)	3.59 (1.13)	0.107
Median (Q1, Q3)	3.40 (3.40, 4.88)	3.77 (3.40, 5.98)	3.40 (3.40, 3.87)	
Min–Max	0.479–13.4	0.479–13.4	1.24–6.68	
Androstenedione (A4)				
Mean (SD)	1.63 (1.65)	1.71 (1.86)	1.44 (1.07)	0.713
Median (Q1, Q3)	1.08 (0.350, 2.47)	0.942 (0.350, 2.51)	1.15 (0.537, 2.17)	
Min–Max	0.0651–7.53	0.0651–7.53	0.168–4.25	
Testosterone (T)				
Mean (SD)	24.5 (6.85)	25.5 (6.60)	22.6 (7.08)	0.148
Median (Q1, Q3)	24.3 (20.3, 28.9)	25.3 (21.3, 29.5)	22.8 (18.5, 28.0)	
Min–Max	7.76–47.3	7.76–47.3	7.81–35.4	
Dihydrotestosterone (DHT)				
Mean (SD)	1.23 (2.90)	1.30 (3.01)	1.07 (2.73)	1
Median (Q1, Q3)	0.170 (0.170, 0.170)	0.170 (0.170, 0.170)	0.170 (0.170, 0.334)	
Min–Max	0.0506–15.2	0.0506–15.2	0.114–11.4	
11 α -hydroxyandrostenedione (11OHA4)				
Mean (SD)	3.37 (1.75)	4.04 (1.62)	2.00 (1.13)	<0.001
Median (Q1, Q3)	3.39 (2.09, 4.14)	3.80 (3.17, 4.61)	1.95 (1.12, 2.63)	
Min–Max	0.330–10.4	1.87–10.4	0.330–4.15	
11-ketoandrostenedione (11KA4)				
Mean (SD)	0.764 (0.365)	0.838 (0.361)	0.611 (0.332)	0.010
Median (Q1, Q3)	0.747 (0.382, 1.01)	0.811 (0.607, 1.05)	0.552 (0.330, 0.777)	
Min–Max	0.300–1.79	0.330–1.79	0.300–1.27	
11 α -hydroxytestosterone (11OHT)				
Mean (SD)	0.567 (0.518)	0.665 (0.590)	0.367 (0.225)	0.006
Median (Q1, Q3)	0.481 (0.285, 0.670)	0.524 (0.366, 0.738)	0.360 (0.212, 0.505)	
Min–Max	0.0300–3.21	0.0879–3.21	0.0300–0.891	
11-ketotestosterone (11KT)				
Mean (SD)	0.440 (0.328)	0.446 (0.318)	0.427 (0.354)	0.748
Median (Q1, Q3)	0.330 (0.303, 0.464)	0.330 (0.306, 0.530)	0.330 (0.299, 0.419)	
Min–Max	0.0127–1.57	0.0127–1.57	0.0258–1.50	
Pregnenolone (P5)				
Mean (SD)	3.57 (0.978)	3.76 (1.12)	3.18 (0.395)	0.007
Median (Q1, Q3)	3.10 (3.10, 3.63)	3.10 (3.10, 4.14)	3.10 (3.10, 3.10)	
Min–Max	2.72–7.63	2.72–7.63	3.10–4.99	
17 α -hydroxypregnenolone (17OHP5)				
Mean (SD)	6.94 (5.86)	8.80 (6.34)	3.13 (1.10)	<0.001
Median (Q1, Q3)	4.52 (3.00, 8.12)	7.37 (3.45, 11.9)	3.00 (3.00, 3.00)	
Min–Max	0.139–29.3	0.139–29.3	1.03–7.53	
Progesterone (P4)				
Mean (SD)	0.101 (0.209)	0.128 (0.243)	0.0464 (0.0932)	0.406
Median (Q1, Q3)	0 (0, 0.0707)	0 (0, 0.127)	0 (0, 0)	
Min–Max	0–0.839	0–0.839	0–0.271	
17 α -hydroxyprogesterone (17OHP4)				
Mean (SD)	0.644 (0.771)	0.511 (0.473)	0.916 (1.13)	0.308
Median (Q1, Q3)	0.300 (0.300, 0.627)	0.300 (0.300, 0.565)	0.300 (0.300, 1.28)	
Min–Max	0.101–4.74	0.133–2.37	0.101–4.74	
16 α hydroxyprogesterone (16OHP4) _u				
Mean (SD)	0.591 (0.424)	0.725 (0.430)	0.319 (0.248)	<0.001
Median (Q1, Q3)	0.520 (0.316, 0.763)	0.628 (0.452, 0.828)	0.245 (0.136, 0.432)	
Min–Max	0–2.30	0.183–2.30	0–0.923	
Continued				

STEROID nmol/L	Overall (n = 70)	DHEA > 7 nmol/L (n = 47)	DHEA < 7 nmol/L (n = 23)	P-value
Cortisol_				
Mean (SD)	338 (150)	396 (119)	218 (137)	< 0.001
Median (Q1, Q3)	339 (224, 465)	359 (311, 488)	183 (117, 254)	
Min–Max	58.8–634	192–634	58.8–591	
Corticosterone (CORT)				
Mean (SD)	14.1 (12.1)	18.2 (11.6)	5.73 (8.18)	< 0.001
Median (Q1, Q3)	7.83 (4.93, 22.7)	16.1 (6.98, 27.1)	2.55 (1.50, 6.73)	
Min–Max	0.530–42.9	3.83–42.9	0.530–39.0	
Cortisone_				
Mean (SD)	55.8 (17.4)	59.6 (12.4)	47.8 (23.0)	0.006
Median (Q1, Q3)	56.5 (45.4, 66.1)	60.6 (50.9, 66.5)	47.9 (31.4, 62.7)	
Min–Max	17.8–108	35.1–85.1	17.8–108	
11-dehydrocorticosterone (11-DHCORT)_				
Mean (SD)	4.40 (2.31)	5.26 (2.01)	2.65 (1.88)	< 0.001
Median (Q1, Q3)	4.48 (2.45, 5.82)	5.14 (3.96, 6.71)	2.04 (1.45, 3.00)	
Min–Max	0.470–10.6	1.43–10.6	0.470–7.77	
Cortisol:cortisone				
Mean (SD)	6.20 (2.97)	6.98 (2.86)	4.62 (2.59)	< 0.001
Median (Q1, Q3)	5.33 (4.06, 7.73)	6.59 (4.79, 8.58)	3.63 (3.27, 5.10)	
Min–Max	2.68–17.3	3.46–17.3	2.68–14.9	

Table 3. Adrenal and gonadal steroid concentrations of healthy males, 18–35 years of age. Concentrations are shown as the mean with the standard deviation (SD), the median and quartiles together with the minimum and maximum ranges. Data show steroid concentrations of the total participant group (n = 70). Comparison of steroid concentrations of participants with DHEA levels lower than 7 nmol/L (n = 23) and participants with DHEA levels higher than 7 nmol/L (n = 47). P-value indicates significant differences between the two groups.

androgen source with age, supplementing the classical androgens. The C11-oxy androgens have, to date not been investigated in androgen deficiency.

We did not detect 11KDHT, 11OHDHT or any C11-oxy progesterones in this study and only low levels of DHT, 11OHT and 11KT. This finding suggests that they are unlikely to contribute to androgen activity in health as they are perhaps insufficient for the activation of the AR at a level equivalent to T². However, the data should be considered with the caveat that circulatory steroid hormones do not necessarily correlate with or reflect steroid levels in tissue, which are likely very different. The presence of the 11-oxy steroids and the potential conversion of C11-oxy progesterones to C11-oxy androgens^{3,4} are in accord with other studies previously investigating hyperandrogenism in which the administration of radiolabelled 21dF resulted in 11OHA4 and 11KAST as well as 11K-Pdiol being detected in both a CAH patient and a control subject, while only 11OH- and 11-keto-etiocholanolone (C11-oxy androgen metabolites) were detected in the CAH patient^{22,23}. In our study the steroids with the highest detection frequency, after T, were the 11-oxy androgens suggesting age defined reference levels need to be determined for the 11-oxy androgens.

What was surprising was the number of normal healthy participants (33%) that had DHEA levels in the lower normal range (below 7 nmol/L); these males were slightly older, 27.0 (Q1 22.8, Q3 29.5) than those with higher DHEA. While it is generally accepted that DHEA declines with age²⁴, this is an unlikely explanation for this relatively young age group. The 11-oxy androgens, 11OHA4, 11KA4 and 11OHT together with 16OHP4 were significantly lower in participants with low DHEA together with the glucocorticoids, cortisol, cortisone, CORT and 11DHCORT. Active glucocorticoids, cortisol and CORT, activate both the glucocorticoid receptor and the mineralocorticoid receptor (MR) with a binding affinity comparable to its natural ligand, ALDO. Regarding the glucocorticoids, 11βHSD2 has a regulatory function converting cortisol and CORT to cortisone and 11-DHCORT respectively. The enzyme thus prevents the activation of the MR by cortisol and CORT, both of which circulate at concentrations far exceeding those of ALDO. The lower glucocorticoid levels in the group with low DHEA were not due to deficient CYP11B since the precursor steroids of CORT and cortisol, 11-deoxycorticosterone and 11-deoxycortisol, respectively were not present in high concentrations. These two steroids were either too low to be detected or too low for accurate quantification. A further observation was that in participants with higher cortisol levels also had 11OHA4 concentrations higher than 5 nmol/L, highlighting the involvement of the adrenal enzyme, CYP11B1, in both glucocorticoid and adrenal androgen production.

Our findings show that in the participants with lower DHEA, fewer steroids were metabolised in adrenal pathways with altered steroids in the glucocorticoid and androgen pathways which speculatively, may be due to an impaired adrenal function possibly relating to signalling pathways involving corticotropin-releasing hormone and adrenocorticotrophic hormone within the hypothalamic–pituitary–adrenal (HPA) axis. Furthermore, participants with low DHEA showed a significant decrease of cortisol:cortisone. Despite this, it is worth noting




Figure 2. Comparison of steroid levels in participants with DHEA levels higher and lower than 7 nmol/L. Data show mean (SD) of all the measured steroid metabolites.

that ratios between 3.9 and 11 are considered normal; therefore males in the low DHEA group were still within the normal range, albeit at the lower end.

Our data emphasise the heterogeneity of steroid levels in healthy individuals, highlighting the need to identify and account for this variability in the investigation of abnormal conditions. If one considers the participants as a single group, all participants appear to be within the norm. Analysis of a single group would not readily identify the participants with different profiles associated with lower circulating DHEA. In addition participants

with altered adrenal steroid production in specific pathways would not be obvious in a single group analysis. Furthermore steroid concentrations measured in participants with lower DHEA would skew normal ranges of a single cohort. Confirmation of this finding and its underlying mechanism will require a much larger cohort and associated laboratory studies.

This study demonstrates that in health 11KT was the lowest of the 11-oxy androgens and ± 7.6 -fold lower than 11OHA4. However the pattern changed in the participants with lower DHEA levels as 11KT is only 4.7-fold lower than 11OHA4 and 11OHT now the lowest of the C11-oxy androgens. This may be of particular importance in the pathogenesis and diagnosis of androgen related disease, for example, high levels of the 11-oxy androgens in PCa and BPH tissue are reported, particularly of 11KT, 11KDHT and 11KP4, with 11KT predominantly in the unconjugated form accumulating in prostate tissue^{12,13}. 11KT is the predominant circulating active C11-oxy androgen in CRPC, suggesting it is a potential driver of CRPC via the AR¹⁰. In addition, 11-oxy androgen levels for 11OHA4, 11KT and 11KAST are associated with metastasis-free survival²⁵. There is increasing interest in 11KT and its role in clinical androgen excess, with two studies reporting significantly increased 11KT in CAH patients compared to controls^{6,26}.

The major strength of this study was the population of healthy men engaging in routine exercise with a narrow age range, medication free with accurate steroid quantification. The shortcomings of our analytical method can be overcome in future studies by focusing on specific steroids related to the investigation and including fewer steroids specific to the investigation. Altered methodology derivatising steroids may improve and enable the detection of steroids present at low concentrations. The finding of a subset of individuals within a cohort of normal young men with low circulating DHEA and altered adrenal steroid production is novel. This exploratory study will facilitate the powering of a definitive study to confirm these findings. Larger studies, covering wider weight categories and accounting for ethnicity, are needed to investigate the A4 and A5 level differences found. This may be particularly relevant for DHT that was not detected in some participants in the higher body weight range. Furthermore, the study highlights that in cases of androgen conditions related to either excess or deficiency, the measurement of T alone is not enough.

In conclusion, steroids other than testosterone significantly contribute to circulating bioactive androgens. We have identified, within a cohort of healthy participants, men with significantly lower DHEA and comparable T but altered adrenal steroids with lower circulating glucocorticoids and lower 11-oxy androgens. Findings highlight steroid heterogeneity in normal young men as well as the contribution of CYP11B1 to glucocorticoid and androgen production. Thus, this study holds importance in terms of the steroids that were identified, as well as those that went undetected, within this cohort of healthy men and may allow the better diagnosis and management of androgen related conditions.

Materials and methods

Reagents

Steroids were purchased from Sigma-Aldrich (St. Louis, USA), Steraloids (Newport, USA) and IsoSciences (Pennsylvania, USA) and deuterated steroid reference standards from Cayman Chemical company (Ann Arbor, Michigan, USA), CDN Isotopes (Augsburg, Bavaria, Germany) and Cambridge Isotopes (Andover, USA). Waters UHPSFC-MS/MS Quality Control (QC) reference material containing trans-stilbene oxide, thymine, sulfamethoxazole and sulfamethizole was purchased from Waters corporation (Milford, USA). Analytical-grade methanol, formic acid, and methyl *tert*-butyl ether (MTBE) were purchased from Sigma-Aldrich (St. Louis, USA).

Study cohort

Healthy males, 71, between 18 and 35 years were eligible study inclusion and recruited by advert. Exclusion criteria: acute or chronic disease, acute or chronic abuse of alcohol, medication intake including counter drug preparations. Data collection took place between September and December 2018. Complete medical histories and medical examinations were undertaken. Fasting blood samples were collected between the hours of 08:00 and 09:00 am to circumvent diurnal variation, centrifuged and the serum was stored at -80°C until analysis. Informed consent was obtained from all subjects/participants and the study was approved by the Institutional Review Board of Weill Cornell Medicine Qatar (Study 1284681-2, IRB no 18000012) and performed in accordance with the Declaration of Helsinki.

UHPSFC-MS/MS analysis

Steroid levels were quantified by validated UHPSFC-MS/MS, allowing the separation of the C₁₉ and 11-oxy C₁₉ steroids, the C₂₁ and 11-oxy C₂₁ steroids, glucocorticoids and mineralocorticoids in a single chromatographic step²⁷. Steroids are listed in Suppl. Table 1 indicating IUPAC and trivial names and abbreviations. Steroids, reference standards and quality control compounds were analysed in multiple reaction monitoring (MRM) mode using positive electrospray ionisation (ESI+) mode, with MS parameter settings together with quantifiers and qualifiers as previously reported. Response factors were calculated for steroid impurities in steroid standards and crosstalk interference between the labelled and unlabelled standards was avoided using unique MRMs. The limit of detection (LOD), lower limit of quantification (LLOQ), calibration range (ng/mL) and linearity (r^2) for each steroid is indicated in Suppl. Table 2.

Free, unconjugated steroids were extracted from 0.5 mL thawed serum using a liquid-liquid extraction method. Samples were spiked with 50 μL internal standard mix containing 15 deuterated steroids (suppl. file), extracted with 5 mL MTBE (10:1 ratio) as reported³⁰, subsequent dried residues were resuspended in 150 μL 50% methanol for analysis. Masslynx 4.1 software (Waters Corporation) was used for data collection and processing.

Statistical analysis

Data analysis was carried out using RStudio (version 4.2.2, RStudio, Boston, MA, US). Analyses were carried out to assess differences in participants with DHEA falling within the normal range (≥ 7 nmol/L) and those with low DHEA concentrations (< 7 nmol/L).

Descriptive statistics (means, standard deviations, medians, and interquartile ranges for continuous variables; counts and percentages for categorical variables) were used to summarise the demographic characteristics of these groups. Differences between groups were examined using Mann–Whitney tests for continuous demographic variables, while Fisher exact tests were used to examine differences in categorical variables. Mann–Whitney U tests also examined steroid levels between participants in the two groups.

For each steroid, the proportion of participants for whom the steroid was not detected (ND) below the LOD and that were detected exceeding the LOD and LLOQ, were calculated. Descriptive statistics, including means, standard deviations, medians, interquartile ranges, and ranges were reported for all steroids, regardless of whether they were detected or exceeded the LOD and LLOQ. The values of undetected steroids were held at zero 1/2 LOD. Differences in steroid levels between the normal and low DHEA groups were examined using Mann–Whitney tests. Finally, Chi-squared tests examined the association between the proportion of participants with DHEA levels above the LLOQ and the proportion of participants with steroid levels above the LLOQ for all other steroids. An a-priori alpha level of 0.05 was selected for all analyses.

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board of Weill Cornell Medicine Qatar (Study 1284681-2, IRB no 18000012) and performed in accordance with the Declaration of Helsinki and its later amendments or comparable ethical standards.

Data availability

All the data for this study will be made available upon reasonable request to the corresponding author.

Received: 6 December 2023; Accepted: 3 July 2024

Published online: 14 July 2024

References

- Barnard, L., du Toit, T. & Swart, A. C. Back where it belongs, 11 β -hydroxyandrostenedione compels the re-assessment of C11-oxy androgens in steroidogenesis. *Mol. Cell. Endocrinol.* **525**, 111189. <https://doi.org/10.1016/j.mce.2021.111189> (2021).
- Bloem, L. M. *et al.* Advances in the analytical methodologies: Profiling steroids in familial pathways-challenging dogmas. *J. Steroid Biochem. Mol. Biol.* **153**, 80–92. <https://doi.org/10.1016/j.jsbmb.2015.04.009> (2015).
- Barnard, L., Gent, R., van Rooyen, D. & Swart, A. C. Adrenal C11-oxy C(21) steroids contribute to the C11-oxy C(19) steroid pool via the backdoor pathway in the biosynthesis and metabolism of 21-deoxycortisol and 21-deoxycortisone. *J. Steroid Biochem. Mol. Biol.* **174**, 86–95. <https://doi.org/10.1016/j.jsbmb.2017.07.034> (2017).
- van Rooyen, D., Gent, R., Barnard, L. & Swart, A. C. The in vitro metabolism of 11 β -hydroxyprogesterone and 11-ketoprogesterone to 11-ketodihydrotestosterone in the backdoor pathway. *J. Steroid Biochem. Mol. Biol.* **178**, 203–212. <https://doi.org/10.1016/j.jsbmb.2017.12.014> (2018).
- Gent, R., du Toit, T., Bloem, L. M. & Swart, A. C. The 11 β -hydroxysteroid dehydrogenase isoforms: Pivotal catalytic activities yield potent C11-oxy C19 steroids with 11 β HSD2 favouring 11-ketotestosterone, 11-ketoandrostenedione and 11-ketoprogesterone biosynthesis. *J. Steroid Biochem. Mol. Biol.* **189**, 116–126. <https://doi.org/10.1016/j.jsbmb.2019.02.013> (2019).
- Bacila, I. *et al.* Measurement of salivary adrenal-specific androgens as biomarkers of therapy control in 21-hydroxylase deficiency. *J. Clin. Endocrinol. Metab.* **104**, 6417–6429. <https://doi.org/10.1210/jc.2019-00031> (2019).
- Caron, P., Turcotte, V. & Guillemette, C. A quantitative analysis of total and free 11-oxygenated androgens and its application to human serum and plasma specimens using liquid-chromatography tandem mass spectrometry. *J. Chromatogr. A* **1650**, 462228. <https://doi.org/10.1016/j.chroma.2021.462228> (2021).
- Schiffer, L. *et al.* Multi-steroid profiling by UHPLC-MS/MS with post-column infusion of ammonium fluoride. *J. Chromatogr. B* **1209**, 123413. <https://doi.org/10.1016/j.jchromb.2022.123413> (2022).
- Bentley, C. *et al.* The ultra-acute steroid response to traumatic injury: A cohort study. *Eur. J. Endocrinol.* **188**, 2902–299. <https://doi.org/10.1093/ajendo/lvad024> (2023).
- Snatser, G. *et al.* 11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration. *JCI Insight* <https://doi.org/10.1172/jci.insight.148507> (2021).
- Hakkinen, M. R. *et al.* Simultaneous analysis by LC-MS/MS of 22 ketosteroids with hydroxylamine derivatization and underivatized estradiol from human plasma, serum and prostate tissue. *J. Pharm. Biomed. Anal.* **164**, 642–652. <https://doi.org/10.1016/j.jpba.2018.11.035> (2019).
- du Toit, T. & Swart, A. C. The 11 β -hydroxyandrostenedione pathway and C11-oxy C(21) backdoor pathway are active in benign prostatic hyperplasia yielding 11keto-testosterone and 11keto-progesterone. *J. Steroid Biochem. Mol. Biol.* **196**, 105497. <https://doi.org/10.1016/j.jsbmb.2019.105497> (2020).
- du Toit, T. *et al.* Profiling adrenal 11 β -hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC(2)-MS/MS quantification of 11 β -hydroxytestosterone, 11keto-testosterone and 11keto-dihydrotestosterone. *J. Steroid Biochem. Mol. Biol.* **166**, 54–67. <https://doi.org/10.1016/j.jsbmb.2016.06.009> (2017).
- Bae, Y. J. *et al.* Reference intervals of nine steroid hormones over the life-span analyzed by LC-MS/MS: Effect of age, gender, puberty, and oral contraceptives. *J. Steroid Biochem. Mol. Biol.* **193**, 105409. <https://doi.org/10.1016/j.jsbmb.2019.105409> (2019).
- Samaras, N., Samaras, D., Frangos, E., Forster, A. & Philippe, J. A. Review of age-related dehydroepiandrosterone decline and its association with well-known geriatric syndromes: Is treatment beneficial?. *Rejuvenation Res.* **16**, 285–294. <https://doi.org/10.1089/rej.2013.1425> (2013).
- Zang, T. *et al.* Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry. *J. Steroid Biochem. Mol. Biol.* **165**, 342–355. <https://doi.org/10.1016/j.jsbmb.2016.08.001> (2017).
- Cussen, L. *et al.* Approach to androgen excess in women: Clinical and biochemical insights. *Clin. Endocrinol.* **97**, 174–186. <https://doi.org/10.1111/cen.14710> (2022).
- Tsametis, C. P. & Isidori, A. M. Testosterone replacement therapy: For whom, when and how?. *Metabolism* **86**, 69–78. <https://doi.org/10.1016/j.metabol.2018.03.007> (2018).

19. Handelsman, D. J. The illusory case for treatment of an invented disease. *Front. Endocrinol.* **12**, 682620. <https://doi.org/10.3389/fendo.2021.682620> (2021).
20. Whitton, K. & Baber, R. Androgen-based therapies in women. *Best Pract. Res. Clin. Endocrinol. Metab.* **38**(1), 101783. <https://doi.org/10.1016/j.beem.2023.101783> (2024).
21. Zumoff, B., Bradlow, H. L., Finkelstein, J., Boyar, R. M. & Hellman, L. The influence of age and sex on the metabolism of testosterone. *J. Clin. Endocrinol. Metab.* **42**, 703–706. <https://doi.org/10.1210/jcem-42-4-703> (1976).
22. Burstein, S., Savard, K. & Dorfman, R. I. The in vivo metabolism of 21-desoxycortisone. *Endocrinology* **53**, 267–273. <https://doi.org/10.1210/endo-53-3-267> (1953).
23. Jailer, J. W., Gold, J. J., Vande Wiele, R. & Lieberman, S. 17alpha-hydroxyprogesterone and 21-desoxyhydrocortisone; their metabolism and possible role in congenital adrenal virilism. *J. Clin. Invest.* **34**, 1639–1646. <https://doi.org/10.1172/JCI103217> (1955).
24. Ceresini, G. *et al.* Evaluation of the circadian profiles of serum dehydroepiandrosterone (DHEA), cortisol, and cortisol/DHEA molar ratio after a single oral administration of DHEA in elderly subjects. *Metabolism* **49**, 548–551. [https://doi.org/10.1016/s0026-0495\(00\)80024-4](https://doi.org/10.1016/s0026-0495(00)80024-4) (2000).
25. Dahmani, C. *et al.* Preoperative circulating 11-oxygenated androgens are associated with metastasis-free survival in localized prostate cancer. *J. Urol.* **209**, 337–346. <https://doi.org/10.1097/JU.0000000000003049> (2023).
26. Zeidler, R. *et al.* Inclusion of 11-oxygenated androgens in a clinical routine LC-MS/MS setup for steroid hormone profiling. *Int. J. Mol. Sci.* <https://doi.org/10.3390/ijms24010539> (2022).
27. du Toit, T., van Rooyen, D., Stander, M. A., Atkin, S. L. & Swart, A. C. Analysis of 52 C(19) and C(21) steroids by UPC(2)-MS/MS: Characterising the C11-oxy steroid metabolome in serum. *J. Chromatogr. B* **1152**, 122243. <https://doi.org/10.1016/j.jchromb.2020.122243> (2020).

Acknowledgements

The authors also wish to thank the Central Analytical Facility staff for their assistance regarding LC-MS.

Author contributions

D.v.R., data acquisition and processing, compiling the first draft, editing; T.d.T and B.H., review and editing; J.M. and M.W., resources and editing; R.L., statistical analysis, writing, review and editing; S.L.A., resources, review and editing; A.C.S. writing, funding acquisition, project administration and student supervision; S.L.A., A.C.S. final revision of manuscript.

Funding

South African National Research Foundation (IFR170125217588, CSUR160414162143), Stellenbosch University (Postgraduate bursary).

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-024-66749-9>.

Correspondence and requests for materials should be addressed to A.C.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024